Hormone-refractory prostate cancer: a multi-step and multi-event process

被引:38
作者
de la Taille, A
Vacherot, F
Salomon, L
Druel, C
de Medina, SGD
Abbou, C
Buttyan, R
Chopin, D
机构
[1] Hop Henri Mondor, Dept Urol, F-94010 Creteil, France
[2] Columbia Presbyterian Med Ctr, Dept Urol, New York, NY 10032 USA
关键词
prostate cancer; hormone refractory; bcl-2; androgen receptor; p53; Fas; ras; LOH; pTEN;
D O I
10.1038/sj.pcan.4500534
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Since the pioneering studies of Huggins in 1941, it has been known that prostate cancer cells, like certain normal epithelial cells, can chronically depend on a critical level of androgenic stimulation for their continuous growth and survival. The entire issue of the development of resistance to androgen ablation therapy for metastatic prostate cancer is based on the fact that a portion of cells can survive without androgen stimulation. The cell mechanism of androgen independent status is unclear. For some authors, a portion of the cells present within a patient with a prostate cancer before therapy is naturally androgen independent (selection hypothesis). However, this hypothesis does not consider gene alteration during prostate cancer natural history and probably hormone-refractory prostate cancer (HRPC) is due to a multi-step and multi-event process. In this literature review, different cell pathways that lead to HRPC are described.
引用
收藏
页码:204 / 212
页数:9
相关论文
共 98 条
[1]  
ABRAHAMSSON PA, 1994, CURR TRENDS EXP ENDO, V2, P21
[2]  
AKAKURA K, 1993, CANCER, V71, P2782, DOI 10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO
[3]  
2-Z
[4]  
Angelsen A, 1997, PROSTATE, V30, P1
[5]  
ANWAR K, 1992, CANCER RES, V52, P5991
[6]   TERMINAL NEUROENDOCRINE DIFFERENTIATION OF HUMAN PROSTATE CARCINOMA-CELLS IN RESPONSE TO INCREASED INTRACELLULAR CYCLIC-AMP [J].
BANG, YJ ;
PIRNIA, F ;
FANG, WG ;
KANG, WK ;
SARTOR, O ;
WHITESELL, L ;
HA, MJ ;
TSOKOS, M ;
SHEAHAN, MD ;
NGUYEN, P ;
NIKLINSKI, WT ;
MYERS, CE ;
TREPEL, JB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (12) :5330-5334
[7]  
Bauer JJ, 1995, CLIN CANCER RES, V1, P1295
[8]  
Beham AW, 1998, INT J MOL MED, V1, P953
[9]   Androgen receptors in prostate cancer [J].
Bentel, JM ;
Tilley, WD .
JOURNAL OF ENDOCRINOLOGY, 1996, 151 (01) :1-11
[10]   HORMONE-RESISTANT PROSTATIC ADENOCARCINOMA - AN EVALUATION OF PROGNOSTIC FACTORS IN PRETREATMENT AND POSTTREATMENT SPECIMENS [J].
BERNER, A ;
NESLAND, JM ;
WAEHRE, H ;
SILDE, J ;
FOSSA, SD .
BRITISH JOURNAL OF CANCER, 1993, 68 (02) :380-384